Cryptococcosis is a systemic fungal infection that often affects adults, especially those who have an alteration in their cellular immunity. Within a year, approximately one million cases of meningeal cryptococcosis in people with acquired immune deficiency syndrome (AIDS) are diagnosed and of these people, almost two-thirds die ([@B35]).

In contrast, worldwide literature has described less than one thousand cases of cryptococcosis in children ([@B30]), including those occurring in immunosuppressed patients. The low frequency of cryptococcosis in children cannot be explained by lack of exposure; in fact, one study shows that the majority of children older than two years have serological evidence of infection by *Cryptococcus neoformans* ([@B14]).

In Colombia, a National Survey on Cryptococcosis that has been conducted since 1993 has allowed us to estimate a more realistic picture of this mycosis ([@B27], [@B12]). The mean annual incidence of cryptococcosis in the general population in Colombia was 2.4 cases per 10^6^ people between 1995-2010; in the population with human immunodeficiency virus (HIV), the incidence ranged between 3-3.3 cases per 10^3^ people ([@B27], [@B12]). With the data obtained from the National Survey, we aimed to analyse the epidemiology and clinical manifestations of cryptococcosis in Colombian children.

PATIENTS, MATERIALS AND METHODS
===============================

*Study design* - This is an observational descriptive study where epidemiological and clinical data from cases of cryptococcosis in children during the years of 1993-2010 were extracted from the National Survey mentioned above.

The National survey was designed in accordance with the guidelines given by the European Confederation of Medical Mycology, with the corresponding authorisation ([@B40]), and processed by clinicians and microbiologists of public, academic and private hospitals, as well as public health laboratories of Colombia.

The survey recorded patient data such as demographic data, sex, year of birth and department (Colombian political divisions), department of residence, risk factors (AIDS, corticosteroid therapy, autoimmune disease, transplantation, solid tumour, haematologic malignancy, diabetes mellitus, kidney failure and cirrhosis), date of clinical diagnosis, signs and symptoms (fever, headache, nausea or vomiting, confusion, mental changes, cough, abnormal vision or loss of vision, focal neurological signs, meningeal signs, hydrocephalus, intracranial hypertension without hydrocephalus, seizures), chest radiographic findings, computerised tomography (CT) and magnetic resonance imaging (MRI). The laboratory results of the tests included the origin of the positive sample for the fungus, results of the direct examination, culture and antigenaemia. Additionally, information was requested for the initial treatment given for cryptococcosis.

The surveys and isolates of the fungus were sent to the two focal points of the study: the National Institutes of Health (INS), in Bogotá, and the Corporation for Biological Research (CIB) of Medellin. With these data, we created a database using the program Epi Info 6.0 that was used for analysis ([@B8]). Children were considered as individual minors of 16 years.

*Ethical considerations* - This study was approved by the Ethical Committee of the CIB. Additionally, this study was endorsed by the technical and ethical committees of the INS.

*Case definition* - A case of cryptococcosis was defined in subjects who presented clinical findings compatible with cryptococcosis in addition to the presence of one or more of the following laboratory results: visualisation of the fungus under direct examination with India ink of cerebrospinal fluid (CSF) from a skin lesion or from a histopathological examination, isolation of *C. neoformans*or*Cryptococcus gattii*from a normally sterile site, bronchoalveolar lavage or skin lesion and a titre ≥ 8 capsular antigen in serum or any titre in the CSF.

An AIDS case was considered in those where HIV infection was reported in the survey and AIDS was not considered in those who were negative for HIV infection or in those for whom this information had not been registered.

*Epidemiological analysis - Prevalence* - The proportion of the number of cases in children was established from the total number of surveys received. This was established at both the national and regional levels.

*Incidence* - The average annual incidence was determined by using as a denominator the average of the population of both Colombia and the departments from 1993-2010, as determined by the National Administrative Department of Statistics ([@B6]). However, an important consideration is that this is a passive and voluntary survey.

*Statistical analysis* - The national incidence rate was determined for each department as well as nationally. Subsequently, these rates were compared using a ratio with the respective confidence interval of 95% using the Poisson distribution and the *p*value was calculated according to a value of 0.05 considered as statistically significant to determine differences in the incidence of disease.

*Microbiology* - The identification of disease was made using conventional methods and species determination was performed using culture in CGB medium ([@B23]). In the first years, the serotype (B or C) was determined using specific antisera commercially available at that time (Crypto-Check, Iatron Laboratories, Japan).

*Molecular type and mating type* - The molecular type was determined in all isolates using polymerase chain reaction fingerprinting with the (GTG)~5~ primer ([@B31]). Mating type a or alpha was determined using specific primers described previously ([@B18]).

*Review of the literature* - A search was performed in the MEDLINE database from 1996 through 30 September 2013 using the following search terms in English: cryptococcosis,*C. neoformans*and *Cryptococcus gattii*, HIV, AIDS, children and epidemiology. In addition, we searched for articles in Spanish and Portuguese in the databases SciELO and LILACS. We took into account the articles that included epidemiological data. We removed the case reports or articles whose full text was not achieved. We added several references cited in articles obtained in the primary search.

RESULTS
=======

*Prevalence, incidence of cases and origin* - A total of 1,578 surveys were received from 76 centres and 25 departments and Bogotá DC over a period of 18 years (1993-2010). Forty-one surveys (2.6%) were from children under 16 years.

Children completing surveys were from the following departments: Cundinamarca/Bogotá DC \[10 (24.3%)\], Norte de Santander \[9 (22%)\], Valle \[5 (12.2%)\], Antioquia \[4 (9.8%)\], Huila \[3 (7.3%)\], Tolima \[3 (7.3%)\], Santander \[2 (4.9%)\], Caquetá \[2 (4.9%)\], Bolívar \[1 (2.4%)\], Nariño \[1 (2.4%)\] and Risaralda \[1 (2.4%)\] ([Fig. 1](#f01){ref-type="fig"}).

Fig. 1: mean annual incidence of cryptococcosis in children \< 16 years.

The mean annual incidence of cryptococcosis in children in Colombia was 0.017 cases per 100,000 children under 16 years; however, in one of the northeastern departments, Norte de Santander, this incidence reached 0.122 cases per 100,000 (p \< 0.0001).

*Demographic information* - The average age of the patients was 8.4 ± 4.7 years and 21 (58.5%) patients were male. The distribution according to age and sex is contained in [Fig. 2](#f02){ref-type="fig"}.

Fig. 2: cryptococcosis in Colombian children 1993-2010.

*Risk factors* - No risk factor was identified in 19 cases (46.3%). The risk factors were HIV infection in 10 patients (24.4%), autoimmune disease, corticosteroid use, haematologic malnutrition and malignancy in three cases each (7.3%) and renal disease, solid tumour and prematurity with one case each (2.3%).

*Clinical findings* - The most frequent clinical manifestations were headache (78.1%), fever (68.8%), nausea and vomiting (65.6%), confusion (50%) and meningeal signs (37.5%). The totals of the clinical manifestations informed are reflected in [Table I](#t01){ref-type="table"}.

TABLE IClinical manifestations of cryptococcosis in childrenClinical findingsn (%)Headache25 (78.1)Fever22 (68.8)Nausea and vomiting21 (65.6)Confusion16 (50)Meningeal signs12 (37.5)Visual alterations9 (28.1)Seizures9 (28.1)Cough6 (18.8)Neurological signs6 (18.8)Hydrocephalus6 (18.8)Loss weight2 (6.2)[^1]

The most common clinical form of presentation of the disease was neurocryptococcosis (87.8%) followed by the disseminated form (12.2%). Among the five patients with disseminated disease, two had skin involvement.

*Diagnostic images* - In five patients, one of them HIV+, results of a chest X-ray were reported and this diagnostic was abnormal in four of them. The abnormality described for each of these was the presence of pulmonary infiltrates. A skull tomography was performed in 14 patients, four of them HIV+, and abnormalities were reported in 10. The abnormalities described were brain hypodensities (3 cases), increase of the meningeal enhancement (3 cases), hydrocephalus (2 cases), calcifications (1 case), brain mass (1 case) and cerebral haemorrhage (1 case). Some patients had more than one abnormality.

*Treatment*- In total, 75.6% of the patients were treated with antifungal agents, two patients did not receive treatment and this information was not available for eight patients. The medication most often used was amphotericin B (AmB) (93.5%). The different therapeutic regimens are listed in [Table II](#t02){ref-type="table"}.

TABLE IIPharmacological treatment of cryptococcosis in Colombian childrenTreatmentn/total (%)Patients with treatment31/41 (75.6)Type of antifungal used AmB29/31 (93.5)5FC4/31 (12.9)FCZ8/31 (25.8)ITZ1/31 (3.2)Caspofungin1/31 (3.2)Therapeutic regimens used AmB only19/31 (61.3)AmB + FCZ5/31 (16.1)AmB + 5FC2/31 (6.4)AmB + 5FC + FCZ1/31 (3.2)AmB + ITZ1/31 (3.2)AmB+ caspofungin1/31 (3.2)5FC + FCZ1/31 (3.2)FCZ only1/31 (3.2)Patients without treatment2/41 (4.9)Patients without treatment information8/41 (19.5)[^2]

*Laboratory diagnosis* - Several diagnostic methods were performed: direct examination, determination of the capsular antigen in serum and CSF and CSF and respiratory samples culture. The results of these tests are described in [Table III](#t03){ref-type="table"}.

TABLE IIIResults of the laboratory examinationsType of examinationn/total (%)Positive direct examination36/38 (94.7)Capsular antigen detection14/14 (100)Serum reactive4/4 (100)CSF reactive10/10 (100)Positive culture34/38 (89.5)Serotype A32/34 (94.1)Serotype B2/34 (5.9)Molecular type VNI29 (85.3)VNII3 (8.8)VGII2 (5.9)Mating type a1 (2.9)alpha33 (97.1)Isolates recovered from CSF27 (79.5)CSF and blood3 (8.9)Blood1 (2.9)Skin1 (2.9)CSF, BAL and skin1 (2.9)Blood and BAL1 (2.9)[^3]

*Serotypes and molecular types* - From a total of 34 isolates studied, 94.1%, were serotype A (molecular patterns VNI (85.3%) and VNII (8.8%) and 5.9 % of the isolates belonged to serotype B, molecular type VGII ([Table III](#t03){ref-type="table"}). From the nine cases identified in Norte de Santander, six isolates were studied and all of them were serotype A, molecular type VNI.

*Literature review* - The results of the review are listed in [Table IV](#t04){ref-type="table"}.

TABLE IVAge, sex, prevalence and incidence of cryptococcosis in children in diverse countries around the worldRegionAge (years)/ findings (%)ReferenceColombia8.4This paperBrazil7.6 and 7.8 (most HIV-)[@B39]8.8 (all HIV-)[@B5]Cuba5.8 (85.7 immunocompetent)[@B21]China7.25 (HIV-)[@B41]10.9 (children up to 17 years)[@B17]South Africa7 (91 HIV +)[@B30]Taiwan13.7 (all HIV- up to 17 years)[@B20]Thailand7 (all HIV+)[@B25]United States of America8 (all HIV+)[@B1]9.8 (all HIV+)[@B24]11.5 (all HIV+)[@B15]11.98 (79.4 immunocompromised, up to 18 years)[@B22]RegionSex male (%)ReferenceColombia58.5This paperBrazil52.8[@B39]Northern Brazil54.5[@B4]Cuba42.9[@B21]China60.87[@B17]South Africa54.9[@B32]57[@B30]Taiwan22.2[@B20]Thailand57.9[@B25]United State of America60.3[@B22]RegionPrevalence (%)ReferenceColombia2.6This paperNorte de Santander29.6[@B26]Northern/northeastern Brazil  State of Bahia32[@B7]State of Pará24[@B4]State of Piauí9.5[@B28]Africa  Botswana Ghana South Africa2.4[@B33]6.9[@B34]2[@B32]RegionPrevalence (%)ReferenceThailand3[@B25]United States of America0.85[@B15]1.4[@B1]3.3[@B19]French Guiana4.6[@B9]Uruguay1.3[@B38]Venezuela0.91[@B36]RegionIncidence (cases x 100,000)ReferenceColombia0.016This paperNorte de Santander0.113This paperChina0.43[@B17]South Africa1 47 (HIV+)[@B30]Gauteng38 (HIV+)[@B29]United States of America100 (HIV+)[@B15]

DISCUSSION
==========

As has been reported in the literature, cryptococcosis is a rare disease in children worldwide, including in Colombia ([@B1], [@B29], [@B30]).

*Age* - The average age of infected children (8.4 years) found in this study is similar to that found in other studies: seven years in South Africa (91% HIV+) ([@B30]), seven years in Thailand (all HIV+) ([@B25]), 7.25 years in China (HIV-) ([@B41]), 7.6, 7.8 and 8.8 years in Brazil (the majority HIV-) ([@B4], [@B5], [@B39]) and eight and 9.8 years in the United States of America (USA) (all HIV+) ([@B24], [@B1]). The average age is greater in China, at 10.9 years (all HIV-) ([@B17]); in other studies from the USA, at 11.5 years (all HIV+) ([@B15]) and 11.98 years (79.4% immunocompromised) ([@B22]) and in Taiwan 13.7% (all HIV-) ([@B20]). In an American study ([@B22]), patients of up to 18 years old were included and in studies from China and Taiwan, patients up to 17 years old were included ([@B20], [@B17]), a fact that could slant the result and increase the average value. In a small Cuban study, the average of age was younger, 5.8 years (85.7% immunocompetent) ([@B21]). In our study, two children less than one year old appeared, a finding only frequent in South Africa, where cryptococcosis in children has a bimodal presentation with a peak at less than one year old and another that appears from five-10 years of age. The high incidence of cryptococcosis in children less than one year is explained in South Africa by the vertical transmission of HIV infection ([@B30]).

*Sex* - In this study, there was a slight predominance of the male sex (58.5%) and similar results were observed in studies from Brazil, 52.6% ([@B4]) and 52.8% ([@B39]), South Africa, 54.9% ([@B32]) and 57% ([@B30]), Thailand, 57.9% ([@B25]), China, 60.87% ([@B17]) and the USA, 60.3% ([@B22]). Some small studies have reported a predominance of the female sex in Taiwan, 77.8% ([@B20]), and Cuba, 57.1% ([@B21]). The predominance of the male sex is more evident in adults, especially in the population infected by HIV ([@B11]).

*Risk factor* - Almost half (46.3%) of the studied patients did not have a known risk factor, a quarter (24.4%) had HIV infection and the rest had other conditions that depressed cellular immunity. In the global literature, studies have been described where all or almost all of the patients had AIDS ([@B24], [@B1], [@B16], [@B25], [@B30]). Additionally, studies exist describing patients without AIDS, but with a percentage of underlying disease, e.g., [@B17] (26.1%) and [@B20] (56%), as do studies of only immunocompetent patients ([@B41]). Other studies exist that include patients with all these possibilities, such as ours and that of [@B22], with 20.6% immunocompetent patients, 22.2% displaying malignancy, 15.9% HIV+ and 41.3% displaying other co-morbidities and that of [@B39], with 24.1% HIV, 25.9% immunocompetent (half of these infected with *C. gattii*) and 50% with another co-morbidity. It is important to highlight the high percentage of immunocompetent patients in our series, which is similar to that described in China, Taiwan and Brazil (dos [@B10], [@B20], [@B28], [@B13], [@B17]).

*Prevalence* - In South Africa, it was estimated that between 0.9-2% of cryptococcosis occurs in children younger than 15 years ([@B29], [@B30]). Additionally, in this same country, 2% of clinical isolates of *Cryptococcus* sp. come from children and 96% of these are HIV+ ([@B32]). In Ghana, cryptococcosis is responsible for 6.9% of meningitis cases, with positive cultures in children under 18 years ([@B34]), and in Botswana, 2.36% of the meningeal cryptococcosis with positive cultures occur in children \< 13 years ([@B33]).

In the northern and northeastern regions of Brazil, a series of childhood cryptococcosis cases have been reported with a high prevalence rate: 32% in the state of Bahia ([@B7]), 24% in the state of Pará ([@B4]) and 9.5% in the state of Piauí ([@B28]). In contrast, French Guiana reported a prevalence of 4.6% ([@B9]). In the USA, the prevalence is lower (0.85-1.4%) in HIV-infected children ([@B15], [@B1]), as is the number of hospitalisations for cryptococcosis, which reached a rate of 6.2 million ([@B22]). In Thailand, 2.97% of hospitalised HIV+ children under 16 years had cryptococcosis ([@B25]) and among those younger than 19 years of age hospitalised for pneumonia, 3.3% have positive serum antigen for *Cryptococcus*, all of them HIV+ ([@B19]). In Latin America, Uruguay registers a prevalence of 1.3% of cryptococcosis in HIV+ children ([@B38]) and Venezuela reported a prevalence of 0.91% in the general population ([@B36]). The prevalence of 2.6% in Colombian children is equally low; however, in a study of meningeal cryptococcosis in HIV- patients in Norte de Santander, 29.6% were children under the age of 16 years ([@B26]), a fact similar to the one reported in northern Brazil ([@B4], [@B7]). Significantly, northern Brazil and Norte de Santander are characterised by a high prevalence of *C. gattii*infection in immunocompetent patients ([@B4], [@B26]).

*Incidence* - Additionally, there are few data on the incidence of cryptococcosis in children. In South Africa, it was calculated that for the year 2007, there was an incidence of one case per 100,000 children in the general population and 47 cases per 100,000 HIV+ children ([@B30]).

In that same country, in the Gauteng province, which has a high rate of prevalence of HIV infection, the incidence of disease is estimated at 38 cases per 100,000 HIV+ children ([@B29]). In an USA study from the end of the last century, an annual incidence of 0.1% among the paediatric population of HIV+ individuals was reported ([@B15]). Recently, China reported an incidence of 0.43 cases per 100,000 children less than 18 years ([@B17]). The incidence of 0.016 cases per 100,000 children under the age of 16 years reported for Colombia in this study is very low compared with what has been reported in other countries; however, in Norte de Santander, the mean annual incidence is seven times higher (0.122 per 100,000), a significant difference from the rest of the country (p \< 0.0001).

The reason for the low presentation of cryptococcosis in children has not been established. It is thought that it is not because of a lack of exposure because a study revealed the presence of IgG and IgM antibodies against the capsule glucuronoxylomannan of *Cryptococcus*sp., both in HIV+ and HIV- children, a fact that supports the idea of an exposure to the fungus or the presence of a subclinical infection early in childhood ([@B2]). Another study carried out in the Bronx, New York, showed that the vast majority of children had antibodies against *Cryptococcus*sp. at the age of two years and that this response persisted throughout childhood ([@B14].

The clinical presentation of disease was mainly neurocryptococcosis (87.8%), a fact also recognised by the majority of the case series ([@B24], [@B1], [@B4], [@B16], [@B25], [@B39], [@B20], [@B17], [@B30], [@B41]), with the exception of the study of [@B22] where the extraneural cryptococcosis was more frequently observed than meningeal cryptococcosis (62% vs. 38%). The most frequent clinical manifestations of headache, fever, nausea and vomiting, mental confusion and meningeal signs are common in most of the published cases. It should be noted that, as in adults, the meningeal signs have a low positivity (37.5%) ([@B27], [@B12]). Unfortunately, the value of the opening pressure of the CSF is not specified and, therefore, we could not establish the percentage of children with intracranial hypertension without hydrocephalus, which in adults exceeds 50% ([@B26]). In only two paediatric series, the value of the CSF pressure was determined and, in both, the percentage of patients with intracranial hypertension was very high: 73.9% in [@B17] and 83% in [@B25]. Almost a fifth of the patients had hydrocephalus, a serious complication of meningeal cryptococcosis. Respiratory compromises were rare and only observed in two patients (4.9%) where the fungus was able to be recovered from bronchoalveolar lavage; likewise, in very few patients (12.2%) were the results of the chest X-ray reported. However, the majority of these patients displayed abnormalities. In only a third of patients, the results of a skull CT were reported, which were abnormal in two-thirds; the abnormalities were multiple, but non-specific. [@B5] reported a series of immunocompetent children with meningitis caused by *C. gattii* with the presence of hypodense nodules in all of them. To a lesser degree, diffuse cerebral atrophy and hydrocephalus was observed; these last two abnormalities coexisted in some cases. In this series, we do not report results of MRI studies.

Treatment was mostly with AmB, alone or in multiple combinations. The treatment of choice for the meningeal cryptococcosis, which was the prevailing form of presentation in our series, is the association of AmB + 5-fluorocytosin. Although there are no controlled studies in children, the results of studies in adults have been extrapolated to children and their use has been recommended by international guidelines for management of this disease ([@B37]).

The mycological diagnosis was made in the vast majority of the cases in the CSF through direct visualisation of the encapsulated yeast cells in the CSF (sensitivity of 94.7%) and for CSF, blood, bronchoalveolar lavage or skin cultures (sensitivity 85.4%). On a smaller scale, the detection of the *Cryptococcus* capsular antigen in CSF and serum was used. These findings are similar to those reported by other investigators ([@B1], [@B4], [@B25], [@B39], [@B20], [@B17], [@B30]) and highlight the utility of direct studies and of culture in the diagnosis of cryptococcosis.

A few of the published reports determined the type of species responsible for cryptococcosis ([@B39], [@B30]). *C. neoformans* var. *grubii* is responsible for the majority of cryptococcosis in the world and, to a greater extent, in patients who are HIV+ ([@B3]). The percentage of 5.9% *C. gattii* in Colombian children is high if compared with the findings of cryptococcosis in the general population of Colombia (3.4-3.8%) ([@B27], [@B12]). In South Africa, 7% of paediatric infections are caused by *C. gattii* ([@B30]) while in Brazil the percentage is much higher, 29.6% ([@B39]).

In recent years, interest in cryptococcosis in children has been on the rise. The National Survey on Cryptococcosis that is being conducted passively in our country has allowed us to estimate the prevalence of cryptococcosis in children in Colombia. However, epidemiological data are still scarce, the factors that determine its relative rarity in the childhood population are still poorly understood and there are no own management guides. Undoubtedly, new studies are needed to improve the handling of children affected by this fungal infection.

To the Colombian group for the study of cryptococcosis, for submitting the surveys, and to the reviewers, for their comments.

[^1]: n = 32.

[^2]: AmB: amphotericin B; FCZ: fluconazole; ITZ: itraconazole; 5FC: 5-fluorocytosin.

[^3]: BAL: bronchoalveolar lavage; CSF: cerebrospinal fluid.
